1. Home
  2. INCY vs CBRS Comparison

INCY vs CBRS Comparison

Compare INCY & CBRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$114.90

Market Cap

24.5B

Sector

Health Care

ML Signal

N/A

Logo Cerebras Systems Inc. Class A Common Stock

CBRS

Cerebras Systems Inc. Class A Common Stock

N/A

Current Price

$84.36

Market Cap

24.0B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
INCY
CBRS
Founded
1991
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
24.5B
24.0B
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
INCY
CBRS
Price
$114.90
$84.36
Analyst Decision
Buy
Strong Buy
Analyst Count
28
11
Target Price
$132.17
★ $210.18
AVG Volume (30 Days)
1.5M
★ 10.5M
Earning Date
10-29-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 4173.33
N/A
EPS
★ 0.50
N/A
Revenue
★ $3,394,635,000.00
N/A
Revenue This Year
$17.74
$82.40
Revenue Next Year
$4.38
$218.73
P/E Ratio
$231.80
★ N/A
Revenue Growth
★ 13.67
N/A
52 Week Low
$89.25
$77.84
52 Week High
$132.60
$265.63

Technical Indicators

Market Signals
Indicator
INCY
CBRS
Relative Strength Index (RSI) 41.81 34.76
Support Level $109.78 $77.84
Resistance Level $119.29 $120.44
Average True Range (ATR) 3.73 9.84
MACD -0.53 1.78
Stochastic Oscillator 3.94 14.97

Price Performance

Historical Comparison
INCY
CBRS

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

About CBRS Cerebras Systems Inc. Class A Common Stock

Cerebras Systems Inc is an AI company. It designs the world's fastest AI infrastructure for training and inference. The company builds the world's largest semiconductor as well as the AI systems to power, cool, and feed the processors data. It develops software to link these systems together into industry-leading supercomputers that are simple to use even for the most complicated AI work, using familiar ML frameworks like PyTorch. Customers use its supercomputers to train industry-leading models. The company uses these supercomputers to run inference at speeds unobtainable from alternative commercial technologies. It delivers these AI capabilities to its customers on-premise and via the cloud. The company generates the majority of its revenue from the USA.

Share on Social Networks: